KR100740761B1 - 단백질 - Google Patents

단백질 Download PDF

Info

Publication number
KR100740761B1
KR100740761B1 KR1020027011130A KR20027011130A KR100740761B1 KR 100740761 B1 KR100740761 B1 KR 100740761B1 KR 1020027011130 A KR1020027011130 A KR 1020027011130A KR 20027011130 A KR20027011130 A KR 20027011130A KR 100740761 B1 KR100740761 B1 KR 100740761B1
Authority
KR
South Korea
Prior art keywords
bcmp
delete delete
breast cancer
protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027011130A
Other languages
English (en)
Korean (ko)
Other versions
KR20030007440A (ko
Inventor
로버트 시몬 보이드
알라스대어 크레이그 스탬프스
조나단 알렉산더 테렛트
Original Assignee
옥스포드 글리코사이언시스(유케이) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0004576.5A external-priority patent/GB0004576D0/en
Priority claimed from GB0031341A external-priority patent/GB0031341D0/en
Application filed by 옥스포드 글리코사이언시스(유케이) 리미티드 filed Critical 옥스포드 글리코사이언시스(유케이) 리미티드
Publication of KR20030007440A publication Critical patent/KR20030007440A/ko
Application granted granted Critical
Publication of KR100740761B1 publication Critical patent/KR100740761B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020027011130A 2000-02-25 2001-02-21 단백질 Expired - Fee Related KR100740761B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0004576.5 2000-02-25
GBGB0004576.5A GB0004576D0 (en) 2000-02-25 2000-02-25 Proteins
GB0031341A GB0031341D0 (en) 2000-12-21 2000-12-21 Protein
GB0031341.1 2000-12-21
PCT/GB2001/000729 WO2001062914A1 (en) 2000-02-25 2001-02-21 Bcmp 84, a protein associated to breast cancer

Publications (2)

Publication Number Publication Date
KR20030007440A KR20030007440A (ko) 2003-01-23
KR100740761B1 true KR100740761B1 (ko) 2007-07-19

Family

ID=26243736

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027011130A Expired - Fee Related KR100740761B1 (ko) 2000-02-25 2001-02-21 단백질

Country Status (14)

Country Link
US (3) US20030130214A1 (enExample)
EP (2) EP1259604A1 (enExample)
JP (1) JP2003524017A (enExample)
KR (1) KR100740761B1 (enExample)
CN (1) CN100384875C (enExample)
AT (1) ATE352311T1 (enExample)
AU (3) AU2001233913A1 (enExample)
BR (1) BR0108659A (enExample)
CA (1) CA2399999A1 (enExample)
DE (1) DE60126248T2 (enExample)
ES (1) ES2279801T3 (enExample)
IL (1) IL151448A0 (enExample)
NZ (1) NZ520967A (enExample)
WO (2) WO2001062784A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
GB0125072D0 (en) * 2001-10-18 2001-12-12 Oxford Glycosciences Uk Ltd Protein
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003087834A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. High throughput analysis of recombinant proteins in multi-well plates
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
CN1745094A (zh) * 2002-12-06 2006-03-08 新加坡综合医院有限公司 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
WO2005029083A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent
EP1693069B1 (en) 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor
JP2007520217A (ja) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
KR101398079B1 (ko) 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN104447975A (zh) * 2014-11-18 2015-03-25 深圳市人口和计划生育科学研究所 一种提取人肿瘤细胞膜蛋白的方法
US20180200331A1 (en) * 2015-07-10 2018-07-19 University Of Iowa Research Foundation Bst-2 as a therapeutic target and diagnostic marker for breast cancer growth and metastasis
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR102312897B1 (ko) * 2021-02-26 2021-10-15 에스케이바이오사이언스(주) 목적 단백질의 고수율 정제방법
CN116854782A (zh) * 2023-06-05 2023-10-10 南京大学 一种果糖探针结合蛋白Tom22及其筛选方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007749A1 (en) * 1996-08-23 1998-02-26 Human Genome Sciences, Inc. Novel human growth factors
WO1999047669A2 (de) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus brusttumorgewebe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196565A2 (en) * 1999-06-30 2002-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007749A1 (en) * 1996-08-23 1998-02-26 Human Genome Sciences, Inc. Novel human growth factors
WO1999047669A2 (de) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus brusttumorgewebe

Also Published As

Publication number Publication date
JP2003524017A (ja) 2003-08-12
WO2001062914A1 (en) 2001-08-30
CA2399999A1 (en) 2001-08-30
AU2001233913A1 (en) 2001-09-03
NZ520967A (en) 2004-04-30
IL151448A0 (en) 2003-04-10
US20070212368A1 (en) 2007-09-13
WO2001062784A3 (en) 2002-01-31
US20030130214A1 (en) 2003-07-10
ATE352311T1 (de) 2007-02-15
US20030099662A1 (en) 2003-05-29
AU3392901A (en) 2001-09-03
BR0108659A (pt) 2002-11-05
EP1257285B1 (en) 2007-01-24
CN1426307A (zh) 2003-06-25
WO2001062784A2 (en) 2001-08-30
CN100384875C (zh) 2008-04-30
KR20030007440A (ko) 2003-01-23
DE60126248T2 (de) 2007-07-05
AU2001233929B2 (en) 2005-09-08
DE60126248D1 (de) 2007-03-15
ES2279801T3 (es) 2007-09-01
EP1257285A2 (en) 2002-11-20
AU2001233929C1 (en) 2006-03-02
HK1056692A1 (zh) 2004-02-27
EP1259604A1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
EP1257285B1 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO2003087831A2 (en) Proteins involved in breast cancer
DK2441775T3 (en) Lymphocyte antigen 75 (Ly75)
AU2001233929A1 (en) Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
JP2003284574A (ja) 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用
US20030064419A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
US20030152935A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
US20100015152A1 (en) Diagnostic and therapeutic methods
US20030017456A1 (en) Diagnosis and treatment and related preparations
JP2003528300A (ja) 神経精神及び神経障害におけるｄｐｉ−６、推定上の治療ターゲットおよびバイオマーカー
AU2005218046B2 (en) Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
US20040053830A1 (en) BCMP84 protein, compositions, diagnostic and therapeutic uses thereof
HK1056692B (en) Proteins
EP1395830B1 (en) Bcmp-101, a cancer associated protein
US20040166517A1 (en) Cancer associated protein
US20040043425A1 (en) Proteins, genes and their use for diagnosis and treatment of chronic asthma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20051031

Effective date: 20070528

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20070528

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2002 7011130

Appeal request date: 20051031

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2005101007447

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100712

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100712